COMP <GO>
MXCT vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
MaxCyte Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MXCT 2
— UNH 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $1.73 (+1.17%) • MKT CAP: $178.5M
roic
-27.10%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MXCT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MXCT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | MXCT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -27.10% | 11.47% | -38.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.26% | 6.48% | -26.74 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -5.70% | 6.46% | -12.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.52 | 3.12 | -1.60 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 59.2 | +6.16 | MXCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $178.5M | $368.83B | -$368.65B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MXCT REV | UNH REV | MXCT GROSS % | UNH GROSS % | MXCT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.0M | $447.57B | 98.0% | 88.7% | -$36.2M | $16.07B |
| FY 2024 | $22.2M | $400.28B | 98.0% | 88.3% | -$29.3M | $20.70B |
| FY 2023 | $19.5M | $371.62B | — | 89.6% | -$21.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MXCT // BETA —
UNH // BETA 0.33